Biocon Biologics Receives Health Canada Approval for Yesintek™ and Yesintek™ I.V. (ustekinumab), a Biosimilar to Stelara®

  • Posted by: Biocon Biologics

Biocon Biologics and Civica Expand Partnership and Launch Private-Label Insulin Glargine to Broaden U.S. Diabetes Treatment Options

  • Posted by: Biocon Biologics

Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars

  • Posted by: Biocon Biologics

Biocon Biologics’ Yesafili® (aflibercept) Now Publicly Funded in Ontario, Canada for the Advanced Treatment of Patients with Retinal Diseases

  • Posted by: Biocon Biologics

Biocon Biologics Receives U.S. Food and Drug Administration Approval for Bosaya™ and Aukelso™, Denosumab Biosimilars

  • Posted by: Biocon Biologics

Biocon Foundation Supports Government High School, Kicks off Construction of a New Building for 250 Students

  • Posted by: Biocon Biologics

U.S. FDA Completes Inspection at Biocon Biologics’ Facility at Biocon Campus, Bengaluru, India

  • Posted by: Biocon Biologics

Biocon Q1FY26 Operating Revenue at Rs 3,942 Cr, Up 15%

  • Posted by: Biocon Biologics

Deepali Naair Appointed as the Global Head – Brand & Corporate Communications at Biocon Biologics

  • Posted by: Biocon Biologics

Biocon Biologics Launches Nepexto®, a Biosimilar to Enbrel® (Etanercept), in Australia

  • Posted by: Biocon Biologics
Share